Arthralgias and myalgias related to quinupristin-dalfopristin administration.

K. M. Olsen, J. A. Rebuck, M. E. Rupp

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.

Original languageEnglish (US)
Pages (from-to)e83-86
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume32
Issue number4
StatePublished - Feb 15 2001

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this